{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:06:28Z","timestamp":1789671988708,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.esmoop.2020.100007","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:46:26Z","timestamp":1610585186000},"page":"100007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Flexible care in breast cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"A.","family":"Wardley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Canon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Elsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pe\u00f1a Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Badovinac Crnjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fredriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2020.100007_bib1","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/hex.12417","article-title":"Treatment-related experiences and preferences of patients with lung cancer: a qualitative analysis","volume":"19","author":"Aumann","year":"2016","journal-title":"Health Expect"},{"key":"10.1016\/j.esmoop.2020.100007_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/tbj.12107","article-title":"Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae","volume":"19","author":"Mosher","year":"2013","journal-title":"Breast J"},{"key":"10.1016\/j.esmoop.2020.100007_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41687-019-0098-1","article-title":"Understanding key symptoms, side effects, and impacts of HR+\/HER2- advanced breast cancer: qualitative study findings","volume":"3","author":"Galipeau","year":"2019","journal-title":"J\u00a0Patient Rep Outcomes"},{"key":"10.1016\/j.esmoop.2020.100007_bib4","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1634\/theoncologist.2015-0110","article-title":"Distance as a barrier to cancer diagnosis and treatment: review of the literature","volume":"20","author":"Ambroggi","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2020.100007_bib5","first-page":"361","article-title":"Transportation as a barrier to cancer treatment","volume":"5","author":"Guidry","year":"1997","journal-title":"Cancer Pract"},{"key":"10.1016\/j.esmoop.2020.100007_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2020.7572","article-title":"Safety at the time of the COVID-19 pandemic: how to keep our oncology patients and healthcare workers safe","volume":"18","author":"Cinar","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2020.100007_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000793","article-title":"ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer","volume":"5","author":"de Azambuja","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2020.100007_bib8","first-page":"430","article-title":"Patients' experiences of receiving chemotherapy in outpatient clinic and\/or onboard a unique nurse-led mobile chemotherapy unit: a qualitative study","volume":"22","author":"Mitchell","year":"2013","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.esmoop.2020.100007_bib9","first-page":"337","volume":"109","author":"Mordenti","year":"2018","journal-title":"Recenti Prog Med"},{"key":"10.1016\/j.esmoop.2020.100007_bib10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-143-11-200512060-00008","article-title":"Hospital at home: feasibility and outcomes of a program to provide hospital-level care at home for acutely ill older patients","volume":"143","author":"Leff","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.esmoop.2020.100007_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1503\/cmaj.081491","article-title":"Avoiding hospital admission through provision of hospital care at home: a systematic review and meta-analysis of individual patient data","volume":"180","author":"Shepperd","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.esmoop.2020.100007_bib12","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1377\/hlthaff.2011.1132","article-title":"Costs for \u2018hospital at home\u2019 patients were 19 percent lower, with equal or better outcomes compared to similar inpatients","volume":"31","author":"Cryer","year":"2012","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.esmoop.2020.100007_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.7000","article-title":"The oncology hospital at home: health care utilization outcomes from the huntsman at home trial","volume":"38","author":"Mooney","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib14","author":"Featherstone"},{"key":"10.1016\/j.esmoop.2020.100007_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5694\/j.1326-5377.2000.tb125563.x","article-title":"A\u00a0randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis","volume":"173","author":"Rischin","year":"2000","journal-title":"Med J Aust"},{"key":"10.1016\/j.esmoop.2020.100007_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2190\/CY03-EV15-K38Y-X4AA","article-title":"Home or hospital? An evaluation of the costs, preferences, and outcomes of domiciliary chemotherapy","volume":"30","author":"King","year":"2000","journal-title":"Int J Health Serv"},{"key":"10.1016\/j.esmoop.2020.100007_bib17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/bmj.322.7290.826","article-title":"Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial","volume":"322","author":"Borras","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.esmoop.2020.100007_bib18","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.bjc.6601420","article-title":"Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study","volume":"89","author":"Anderson","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2020.100007_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.05.003","article-title":"Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small-cell lung cancer","volume":"89","author":"Lal","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2020.100007_bib20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.esmoop.2020.100007_bib24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00277-017-3147-y","article-title":"SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma","volume":"97","author":"Fargier","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.esmoop.2020.100007_bib26","doi-asserted-by":"crossref","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"De Cock","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2020.100007_bib27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.clinthera.2017.05.342","article-title":"Microcosting study of rituximab subcutaneous injection versus intravenous infusion","volume":"39","author":"Mihajlovic","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.esmoop.2020.100007_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib29","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1060028013503122","article-title":"Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences","volume":"47","author":"Barbee","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.esmoop.2020.100007_bib30","first-page":"308","article-title":"Subcutaneous administration of bortezomib: a pilot survey of oncology nurses","volume":"6","author":"Martin","year":"2013","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib34","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2016.67.0182","volume":"34","author":"Denduluri","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib35","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1200\/JCO.2018.78.8604","article-title":"Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update","volume":"36","author":"Denduluri","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000489329","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2018","volume":"13","author":"Liedtke","year":"2018","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.esmoop.2020.100007_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000489331","article-title":"AGO recommendations for the diagnosis and treatment of patients with advanced and metastatic breast cancer: update 2018","volume":"13","author":"Thill","year":"2018","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.esmoop.2020.100007_bib38","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib39","doi-asserted-by":"crossref","first-page":"e190339","DOI":"10.1001\/jamaoncol.2019.0339","article-title":"Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial","volume":"5","author":"Jackisch","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib40","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"suppl 24","key":"10.1016\/j.esmoop.2020.100007_bib41","article-title":"Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: cohort 2 of the PrefHer study","volume":"73","author":"Pivot","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2020.100007_bib42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2017.08.019","article-title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study","volume":"86","author":"Pivot","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2020.100007_bib43","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","article-title":"Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","volume":"25","author":"Pivot","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.breast.2015.01.002","article-title":"Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study","volume":"24","author":"Fallowfield","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2020.100007_bib45","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1055\/s-0035-1546172","article-title":"Subcutaneous trastuzumab for HER2-positive breast cancer \u2013 evidence and practical experience in 7 German centers","volume":"75","author":"Jackisch","year":"2015","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.esmoop.2020.100007_bib46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.breast.2016.07.008","article-title":"Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer \u2013 an observational study prospectively recording resource utilization in a Swedish healthcare setting","volume":"29","author":"Olofsson","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2020.100007_bib47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2017.05.009","article-title":"Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetaspHer study","volume":"82","author":"Pivot","year":"2017","journal-title":"Eur J Cancer"},{"issue":"suppl 24","key":"10.1016\/j.esmoop.2020.100007_bib48","article-title":"Subcutaneous trastuzumab (Herceptin\u00ae): a UK Time and Motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer","volume":"73","author":"Burcombe","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2020.100007_bib49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cam4.573","article-title":"A\u00a0time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer","volume":"5","author":"De Cock","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2020.100007_bib50","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s12094-017-1684-4","article-title":"Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain","volume":"19","author":"Lopez-Vivanco","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejogrb.2017.12.006","article-title":"Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: a time, motion and cost assessment study in a lean operating day care oncology unit","volume":"221","author":"Tjalma","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.esmoop.2020.100007_bib52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/cer-2017-0048","article-title":"Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer","volume":"7","author":"Olsen","year":"2018","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.esmoop.2020.100007_bib53","unstructured":"Abad R, Arenaza A, Bayo J, et\u00a0al. 2018. Impacto en la eficiencia tras la optimizaci\u00f3n de recursos con la v\u00eda subcut\u00e1nea de trastuzumab y rituximab en los hospitales espa\u00f1oles. \u201cProyecto H-Excelencia\u201d 6th Tendiendo Puentes (Congreso De Oncologia Medica, Hematologia y Farmacia Oncohematologica). November 22-24, 2018; Toledo, Spain."},{"key":"10.1016\/j.esmoop.2020.100007_bib54","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bulcan.2018.07.014","volume":"105","author":"Favier","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.esmoop.2020.100007_bib55","doi-asserted-by":"crossref","first-page":"PCN85","DOI":"10.1016\/j.jval.2018.09.167","article-title":"Saving healthcare and societal costs by changing the route of administration of oncology drugs","volume":"21","author":"Franken","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.esmoop.2020.100007_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10549-020-05604-7","article-title":"Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer","volume":"181","author":"Denys","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2020.100007_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00280-015-2922-5","article-title":"Population pharmacokinetic and exposure\u2013response analysis for trastuzumab administered using a subcutaneous \u201cmanual syringe\u201d injection or intravenously in women with HER2-positive early breast cancer","volume":"77","author":"Quartino","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2020.100007_bib59","series-title":"Care Closer to Home and Medicines Optimisation","year":"2015"},{"key":"10.1016\/j.esmoop.2020.100007_bib60","series-title":"Impact of Switching from Intravenous to Subcutaneous Trastuzumab in the Management of HER2 Positive Breast Cancer","author":"Roe","year":"2016"},{"key":"10.1016\/j.esmoop.2020.100007_bib61","unstructured":"Snell A, Ford M. Assessing the impact of a homecare\/mobile chemotherapy unit co-ordinator using subcutaneous herceptin as an example. UKONS Annual Conference 2016. November 11-12, 2016; Brighton, UK."},{"key":"10.1016\/j.esmoop.2020.100007_bib62","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.bulcan.2018.10.005","volume":"105","author":"Pailler","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.esmoop.2020.100007_bib66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib67","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib68","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2020.100007_bib69","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100007_bib70","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2020.100007_bib71","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/jcph.1362","article-title":"Development of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab: results from the phase Ib dose-finding study","volume":"59","author":"Kirschbrown","year":"2019","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2020.100007_bib72","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","author":"Tan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2020.100007_bib73","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/j.annonc.2020.08.287","article-title":"Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): primary analysis of the open-label, randomised crossover PHranceSCa study.","volume":"31","author":"O'Shaughnessy","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2020.100007_bib74","article-title":"Cost-minimisation analysis of subcutaneous versus intravenous trastuzumab for the treatment of early breast cancer and metastatic breast cancer in Singapore","volume":"21","author":"Ghosh","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.esmoop.2020.100007_bib75","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/CAD.0000000000000648","article-title":"Potential cost savings owing\u00a0to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands","volume":"29","author":"Franken","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.esmoop.2020.100007_bib76","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3747\/co.25.4231","article-title":"Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites","volume":"25","author":"Stewart","year":"2018","journal-title":"Curr Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920328696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920328696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:14Z","timestamp":1761855914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920328696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2059702920328696"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2020.100007","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flexible care in breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2020.100007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Limited on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100007"}}